The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...